Pfizer’s Monthly Obesity Injection Yields Up to 12.3% Weight Loss
In a mid‐stage Phase 2 trial, Pfizer’s PF-3944 obesity injection achieved up to 12.3% weight loss versus placebo at week 28 and 10.5% across all patients with once-monthly dosing. No weight-loss plateau was observed through monthly dosing, fueling ten-trial Phase 3 program and coinciding with a nearly 3% premarket drop.
1. Phase II Trial Demonstrates Robust Weight Loss with Monthly Dosing
In the ongoing VESPER-3 Phase II study, Pfizer’s ultra–long-acting GLP-1 receptor agonist PF-3944 produced up to 12.3% mean body-weight reduction versus placebo at week 28 among adults with obesity or overweight. Analysis of all randomized patients, including discontinuations, showed sustained weight losses of up to 10.5%. Patients received weekly injections for 12 weeks before transitioning to monthly maintenance dosing, with no observed plateau in weight loss through week 28 and continued downward trajectories expected through week 64.
2. Tolerability and Safety Profile Align with Class Standards
PF-3944 was generally well tolerated over both weekly and monthly regimens, with most reported gastrointestinal events characterized as mild or moderate. Across dosing cohorts, ten patients discontinued treatment due to adverse events—five during the weekly induction phase and five during monthly maintenance—comparable to rates seen with existing GLP-1 therapies. No new safety signals were identified, supporting the agent’s favorable risk-benefit profile.
3. Strategic Implications and Phase III Roadmap
Buoyed by these mid-stage data, Pfizer plans to initiate ten pivotal Phase III trials for PF-3944 this year, evaluating two maintenance regimens—the low and medium monthly doses selected from Phase II—and exploring combination regimens targeting additional gut-hormone pathways. Internal modeling shared on the Q4 earnings call projects that a higher monthly maintenance dose could yield approximately 16% mean weight loss at week 28 in late-stage studies. Success in these trials could position PF-3944 as the first once-monthly obesity injection, offering a differentiated convenience profile against dominant weekly products from Novo Nordisk and Eli Lilly.
4. Market Opportunity and Competitive Landscape
The obesity-treatment market is projected to exceed $35 billion by 2030, driven by rising global prevalence and demand for effective, patient-friendly regimens. PF-3944’s monthly schedule may capture a segment of patients and providers seeking reduced visit frequency compared to weekly injections and daily oral agents. While Novo Nordisk’s Wegovy and Lilly’s Mounjaro hold current market leadership with weekly dosing, Pfizer’s long-acting profile could allow payers and health systems to optimize adherence, potentially translating into durable real-world outcomes and differentiated value propositions.